Optimal Timing of Postoperative Magnetic Resonance Imaging (MRI) in Patients With Extradural Spinal

Sponsor
Case Comprehensive Cancer Center (Other)
Overall Status
Completed
CT.gov ID
NCT02790294
Collaborator
(none)
8
1
1
51.5
0.2

Study Details

Study Description

Brief Summary

This research study is evaluating suitability of a delayed magnetic resonance imaging (MRI) in management of spine tumors. Currently the standard of care is obtaining an MRI scan in the early postoperative period (within 72 hours after surgery). The purpose of this study is to see if delayed MRI (2 to 3 weeks after surgery) is similar in quality to the earlier MRI.

In this study patients will undergo 2 MRIs after the surgery instead of one MRI. Patients will have one MRI about 3 days after the surgery and one MRI about 2-3 weeks after surgery.

Condition or Disease Intervention/Treatment Phase
  • Device: Magnetic Resonance Imaging
N/A

Detailed Description

Primary aim:

Assess if Magnetic Resonance Imaging (MRI) at 2 to 3 weeks after surgery leads to the same clinical decisions and has the same probability of being chosen by a physician for guiding the subsequent management of the patient, compared with immediately postoperative MRI.

Secondary aims:
Investigate the differences between early and late MRI by comparing:
  • Size of tumor in three dimensions;

  • Extent of edema;

  • Presence and extent of fluid collection;

  • Spine Oncology Study Group score;

  • Involvement of adjacent levels;

  • Progression of tumor;

  • Patient's preference/performance scale right after each image had taken: level of discomfort at around the time each MRI was performed.

Study Design:

This is a prospective diagnostic study for which no standard of care currently exists.

Study Design

Study Type:
Interventional
Actual Enrollment :
8 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Optimal Timing of Postoperative Magnetic Resonance Imaging (MRI) in Patients With Extradural Spinal Tumors - a Pilot Study
Actual Study Start Date :
Aug 31, 2016
Actual Primary Completion Date :
Dec 17, 2020
Actual Study Completion Date :
Dec 17, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Postoperative Magnetic Resonance Imaging

Three MRIs will be performed. One at baseline, one within 72 hours postoperative, and one 2-3 weeks postoperative.

Device: Magnetic Resonance Imaging
The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
Other Names:
  • MRI
  • Outcome Measures

    Primary Outcome Measures

    1. Number of patients which have the same clinical decision from the immediate postoperative MRI and later imaging [Up to 3 weeks after surgery]

      Assess if Magnetic Resonance Imaging (MRI) at 2 to 3 weeks after surgery (aka: later imaging) leads to the same clinical decisions and has the same probability of being chosen by a physician for guiding the subsequent management of the patient, compared with immediately postoperative MRI (within 72 hours, aka: early imaging).

    Secondary Outcome Measures

    1. Change in tumor volume between immediate and later postoperative MRI [Up to 3 weeks after surgery]

    2. Difference in level of discomfort as measured by a visual analog scale between postoperative MRIs [Up to 3 weeks after surgery]

    3. Progression of tumor using RECIST Criteria [Up to 3 weeks after surgery]

      RECIST response categories: Progressive disease (PD): >=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): >=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Metastatic or primary malignant tumor involving spinal column, with or without extension into the epidural space

    • Operated for debulking, decompression or separation surgery;

    • A magnetic resonance imaging (MRI) scan performed within 72 hours after surgery is needed;

    • Image quality acceptable for comparison with later MRI as read by a neuroradiologist;

    • Karnofsky score of 60 or higher;

    • Able to consent for the study.

    Exclusion Criteria:
    • Any patient who previously underwent spinal surgery at these levels will be excluded to eliminate late postoperative changes.

    • Intradural extension of the tumor.

    • Patients, whose MRI at post operative 48-72 hours are not readable due to artifacts or disease process shall not be included in the study.

    • Patient not able to tolerate MRI scan due to claustrophobia or severe pain or allergic reaction to contrast.

    • Patients with an estimated Glomerular Filtration Rate (eGFR) < or = to 30 will be excluded to avoid issues related to contrast administration in such patients. This Glomerular Filtration Rate (GFR) threshold cutoff level is chosen per institutional policy, because below that level other measures would be required (hydration or no contrast administration). In order to keep the imaging information as uniform as possible in such a small study group, patients with a low GFR will not be enrolled in the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland Ohio United States 44195

    Sponsors and Collaborators

    • Case Comprehensive Cancer Center

    Investigators

    • Principal Investigator: Lilyana Angelov, MD, Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Case Comprehensive Cancer Center
    ClinicalTrials.gov Identifier:
    NCT02790294
    Other Study ID Numbers:
    • CASE4314
    First Posted:
    Jun 3, 2016
    Last Update Posted:
    May 6, 2021
    Last Verified:
    May 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Keywords provided by Case Comprehensive Cancer Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 6, 2021